• Describe female sexual dysfunction (FSD) and the four classifications of FSD
• Review the epidemiologic data associated with FSD and describe the prevalence of each type
• Explain the important components to be included in a sexual health evaluation
• Discuss the role of the PA in initiating a sexual health dialogue
A basic knowledge of the types of female sexual dysfunction and their prevalence can help physician assistants with initiating a discussion on this vital aspect of women's health.
EARN CATEGORY I CME CREDIT by reading this article and the article beginning on page 42 and successfully completing the posttest on page 47. Successful completion is defined as a cumulative score of at least 70% correct. This material has been reviewed and is approved for 1 hour of clinical Category I (Preapproved) CME credit by the AAPA. The term of approval is for 1 year from the publication date of June 2010.
Raymond Cox is Chairman, Department of Obstetrics and Gynecology, Saint Agnes Hospital, Baltimore, Maryland, and immediate past-Chair, American College of Obstetricians and Gynecologists Committee on the Health of Underserved Women. He has no relationships to disclose relating to the content of this article. Laura Moore is Senior Regional Medical Scientist, Boehringer Ingelheim Pharmaceuticals Inc, Ellicott City, Maryland, and practices in obstetrics and gynecology at Saint Agnes Hospital. Boehringer Ingelheim is the developer of flibanserin, an experimental treatment for female sexual disfunction.